Merus NV
NASDAQ:MRUS
Intrinsic Value
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. [ Read More ]
The intrinsic value of one MRUS stock under the Base Case scenario is 35.95 USD. Compared to the current market price of 40.47 USD, Merus NV is Overvalued by 11%.
Valuation Backtest
Merus NV
Run backtest to discover the historical profit from buying and selling MRUS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Merus NV
Current Assets | 368.8m |
Cash & Short-Term Investments | 354.4m |
Receivables | 4m |
Other Current Assets | 10.5m |
Non-Current Assets | 86.7m |
Long-Term Investments | 57.3m |
PP&E | 23.5m |
Intangibles | 1.8m |
Other Non-Current Assets | 4.1m |
Current Liabilities | 69.1m |
Accounts Payable | 4.6m |
Accrued Liabilities | 40.2m |
Other Current Liabilities | 24.3m |
Non-Current Liabilities | 30.1m |
Other Non-Current Liabilities | 30.1m |
Earnings Waterfall
Merus NV
Revenue
|
43.9m
USD
|
Operating Expenses
|
-200.5m
USD
|
Operating Income
|
-156.5m
USD
|
Other Expenses
|
1.6m
USD
|
Net Income
|
-154.9m
USD
|
Free Cash Flow Analysis
Merus NV
What is Free Cash Flow?
MRUS Profitability Score
Profitability Due Diligence
Merus NV's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Merus NV's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
MRUS Solvency Score
Solvency Due Diligence
Merus NV's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Merus NV's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MRUS Price Targets Summary
Merus NV
According to Wall Street analysts, the average 1-year price target for MRUS is 62.05 USD with a low forecast of 52.52 USD and a high forecast of 72.45 USD.
Ownership
MRUS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MRUS Price
Merus NV
Average Annual Return | 9.97% |
Standard Deviation of Annual Returns | 58.78% |
Max Drawdown | -49% |
Market Capitalization | 2.3B USD |
Shares Outstanding | 58 687 600 |
Percentage of Shares Shorted | 5.91% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 121 full-time employees. The company went IPO on 2016-05-19. The firm develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Contact
IPO
Employees
Officers
The intrinsic value of one MRUS stock under the Base Case scenario is 35.95 USD.
Compared to the current market price of 40.47 USD, Merus NV is Overvalued by 11%.